WHO Recommends Two New Vaccine Candidates for Ebola Trial in DRC

The World Health Organization (WHO) has recommended the addition of two new Ebola vaccine candidates, ChAdOx1 (University of Oxford/Serum Institute of India) and mRNA-1469 (Moderna), to the ongoing Tumaini clinical trial in the Democratic Republic of the Congo (DRC). This marks the first time vaccines specifically targeting the Bundibugyo virus, responsible for the current outbreak, will be evaluated during an active outbreak.